临床试验/NCT00657319

NCT00657319已完成不适用

Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins

Novo Nordisk A/S1 个研究点分布在 1 个国家目标入组 3,495 人开始时间: 2007年10月最近更新: 2017年1月9日

适应症

干预措施

试验速览

阶段: 不适用
状态: 已完成
发起方: Novo Nordisk A/S
入组人数: 3,495
试验地点: 1
主要终点: HbA1C

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This observational study is conducted in Europe. The objective of this retrospective observational cohort analysis is to assess the changes of glycaemic control and quality of care in those Type 2 diabetic patients who were previously treated with Mixtard® insulins after 6 months of their switch to analog premix insulin NovoMix® 30 therapy.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Retrospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Subjects diagnosed with type 2 diabetes previously treated with BHI for at least 12 months
•Analogue premix administration for the last 6 months

排除标准

•Known or suspected allergy to insulin aspart
•Newly diagnosed diabetes

研究组 & 干预措施

A

干预措施: biphasic insulin aspart 30 (Drug)

结局指标

主要结局

HbA1C

时间窗: 6 months

次要结局

General conditions (reason of switch, BMI, selected laboratory parameters, quality of care)(6 months)

研究者

发起方

Novo Nordisk A/S

申办方类型

Industry

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

已完成

不适用

Observational Study in Type 2 Diabetics Failing on Oral Antidiabetic Therapy and Starting on Insulin TreatmentDiabetesDiabetes Mellitus, Type 2

NCT00865397Novo Nordisk A/S1,032

已完成

不适用

Observational Study of Glycaemic Control in Patients Uncontrolled on Oral Antidiabetic Agents and Starting With 1 (Once) Daily Levemir® (Insulin Detemir) as the Treatment of Type 2 Diabetes MellitusDiabetesDiabetes Mellitus, Type 2

NCT00687284Novo Nordisk A/S2,188

已完成

不适用

Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern InsulinDiabetesDiabetes Mellitus, Type 2

NCT00670722Novo Nordisk A/S6,500

已完成

不适用

Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 DiabetesDiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1

NCT00699179Novo Nordisk A/S2,308

已完成

不适用

Observational Study Describing Conditions for Administering Slow-acting Insulin Analogue With Oral Antidiabetic Agents in Type 2 Diabetes on Blood Glucose ControlDiabetesDiabetes Mellitus, Type 2

NCT00700960Novo Nordisk A/S2,745